215 related articles for article (PubMed ID: 33475867)
1. Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.
Harris DM; Stancampiano FF; Burton MC; Moyer AM; Schuh MJ; Valery JR; Bi Y
Dig Dis Sci; 2021 Dec; 66(12):4120-4127. PubMed ID: 33475867
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Lima JJ; Thomas CD; Barbarino J; Desta Z; Van Driest SL; El Rouby N; Johnson JA; Cavallari LH; Shakhnovich V; Thacker DL; Scott SA; Schwab M; Uppugunduri CRS; Formea CM; Franciosi JP; Sangkuhl K; Gaedigk A; Klein TE; Gammal RS; Furuta T
Clin Pharmacol Ther; 2021 Jun; 109(6):1417-1423. PubMed ID: 32770672
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.
Lima JJ; Franciosi JP
Pharmacogenomics; 2014 Aug; 15(11):1405-16. PubMed ID: 25303292
[TBL] [Abstract][Full Text] [Related]
4. Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease.
Elchynski AL; Cicali EJ; Ferrer Del Busto MC; Hamilton A; Chang KL; Schmidt SO; Weiner B; Davis R; Estores D; Max Smith D; Wiisanen K; Johnson JA; Cavallari LH
Pharmacogenomics J; 2021 Dec; 21(6):657-663. PubMed ID: 34075203
[TBL] [Abstract][Full Text] [Related]
5. Association between migraine prevalence, treatment with proton-pump inhibitors and CYP2C19 phenotypes in UK Biobank.
Pisanu C; Welander NZ; Rukh G; Schiöth HB; Mwinyi J
Biomed Pharmacother; 2021 Nov; 143():112234. PubMed ID: 34649359
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.
El Rouby N; Lima JJ; Johnson JA
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):447-460. PubMed ID: 29620484
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
Fedorinov DS; Mirzaev KB; Ivashchenko DV; Temirbulatov II; Sychev DA; Maksimova NR; Chertovskih JV; Popova NV; Tayurskaya KS; Rudykh ZA
Drug Metab Pers Ther; 2018 Jun; 33(2):91-98. PubMed ID: 29738309
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 polymorphism influences Helicobacter pylori eradication.
Kuo CH; Lu CY; Shih HY; Liu CJ; Wu MC; Hu HM; Hsu WH; Yu FJ; Wu DC; Kuo FC
World J Gastroenterol; 2014 Nov; 20(43):16029-36. PubMed ID: 25473155
[TBL] [Abstract][Full Text] [Related]
9. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Empey PE; Stevenson JM; Tuteja S; Weitzel KW; Angiolillo DJ; Beitelshees AL; Coons JC; Duarte JD; Franchi F; Jeng LJB; Johnson JA; Kreutz RP; Limdi NA; Maloney KA; Owusu Obeng A; Peterson JF; Petry N; Pratt VM; Rollini F; Scott SA; Skaar TC; Vesely MR; Stouffer GA; Wilke RA; Cavallari LH; Lee CR;
Clin Pharmacol Ther; 2018 Oct; 104(4):664-674. PubMed ID: 29280137
[TBL] [Abstract][Full Text] [Related]
10. Update on the pharmacogenomics of proton pump inhibitors.
Hagymási K; Müllner K; Herszényi L; Tulassay Z
Pharmacogenomics; 2011 Jun; 12(6):873-88. PubMed ID: 21692617
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.
Chaudhry AS; Kochhar R; Kohli KK
Indian J Med Res; 2008 Jun; 127(6):521-30. PubMed ID: 18765869
[TBL] [Abstract][Full Text] [Related]
12. Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.
Franciosi JP; Mougey EB; Williams A; Gomez Suarez RA; Thomas C; Creech CL; George K; Corao D; Lima JJ
Eur J Pediatr; 2018 Jan; 177(1):69-77. PubMed ID: 29209919
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of proton pump inhibitors.
Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
[TBL] [Abstract][Full Text] [Related]
14. Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center.
Cicali EJ; Elchynski A; Thomas CD; Alam B; Dalton R; Davis R; Eken E; Estores D; Nguyen K; Cavallari LH; Wiisanen K
Am J Health Syst Pharm; 2023 Jul; 80(15):994-1003. PubMed ID: 37166240
[TBL] [Abstract][Full Text] [Related]
15. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
[TBL] [Abstract][Full Text] [Related]
16. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
[TBL] [Abstract][Full Text] [Related]
17. A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens.
Chevalier R; Attard T; Van Driest SL; Shakhnovich V
Expert Opin Drug Metab Toxicol; 2023 Feb; 19(2):53-56. PubMed ID: 36919492
[No Abstract] [Full Text] [Related]
18. Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.
Cicali EJ; Blake K; Gong Y; Mougey EB; Al-Atrash H; Chambers N; Denham J; Evans J; George DE; Gomez R; Palomo P; Taufiq S; Johnson JA; Lima JJ; Franciosi JP
Clin Transl Sci; 2019 Mar; 12(2):172-179. PubMed ID: 30341969
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes and Sustainability of Using
Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics fail to explain proton pump inhibitor refractory esophagitis in pediatric esophageal atresia.
Yasuda JL; Staffa SJ; Nurko S; Kane M; Wall S; Mougey EB; Franciosi JP; Manfredi MA; Rosen R
Neurogastroenterol Motil; 2022 Jan; 34(1):e14217. PubMed ID: 34337835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
